Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleClinical Investigation
Open Access

A Randomized, Factorial Phase II Study to Determine the Optimal Dosing Regimen for 68Ga-Satoreotide Trizoxetan as an Imaging Agent in Patients with Gastroenteropancreatic Neuroendocrine Tumors

Irene Virgolini, Shadfar Bahri, Andreas Kjaer, Henning Grønbæk, Peter Iversen, Esben A. Carlsen, Mathias Loft, Ulrich Knigge, Johanna Maffey-Steffan, Christine Powell, Colin G. Miller, Thomas Rohban, Sandy McEwan and Johannes Czernin
Journal of Nuclear Medicine March 2022, 63 (3) 376-383; DOI: https://doi.org/10.2967/jnumed.121.261936
Irene Virgolini
1Department of Nuclear Medicine, University of Innsbruck, Innsbruck, Austria;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shadfar Bahri
2Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andreas Kjaer
3Department of Clinical Physiology, Nuclear Medicine and PET and Cluster for Molecular Imaging, Department of Biomedical Sciences, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Henning Grønbæk
4Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Iversen
5Department of Nuclear Medicine and PET Center, Aarhus University Hospital, Aarhus, Denmark;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Esben A. Carlsen
3Department of Clinical Physiology, Nuclear Medicine and PET and Cluster for Molecular Imaging, Department of Biomedical Sciences, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mathias Loft
3Department of Clinical Physiology, Nuclear Medicine and PET and Cluster for Molecular Imaging, Department of Biomedical Sciences, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ulrich Knigge
6Department of Endocrinology PE and Department of Surgery C, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Johanna Maffey-Steffan
1Department of Nuclear Medicine, University of Innsbruck, Innsbruck, Austria;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christine Powell
7Ipsen Bioscience, Cambridge, Massachusetts;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Colin G. Miller
8Bracken Group for Ipsen Bioscience, Newtown, Pennsylvania; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Rohban
9Partner 4 Health for Ipsen Bioscience, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sandy McEwan
7Ipsen Bioscience, Cambridge, Massachusetts;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Johannes Czernin
2Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 63 no. 3 376-383
DOI 
https://doi.org/10.2967/jnumed.121.261936
PubMed 
34215673

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Received for publication January 15, 2021
  • Revision received June 7, 2021
  • Published online March 1, 2022.

Article Versions

  • previous version (July 2, 2021 - 13:29).
  • You are viewing the most recent version of this article.
Copyright & Usage 
© 2022 by the Society of Nuclear Medicine and Molecular Imaging. Immediate Open Access: Creative Commons Attribution 4.0 International License (CC BY) allows users to share and adapt with attribution, excluding materials credited to previous publications. License: https://creativecommons.org/licenses/by/4.0/. Details: http://jnm.snmjournals.org/site/misc/permission.xhtml.

Author Information

  1. Irene Virgolini1,
  2. Shadfar Bahri2,
  3. Andreas Kjaer3,
  4. Henning Grønbæk4,
  5. Peter Iversen5,
  6. Esben A. Carlsen3,
  7. Mathias Loft3,
  8. Ulrich Knigge6,
  9. Johanna Maffey-Steffan1,
  10. Christine Powell7,
  11. Colin G. Miller8,
  12. Thomas Rohban9,
  13. Sandy McEwan7 and
  14. Johannes Czernin2
  1. 1Department of Nuclear Medicine, University of Innsbruck, Innsbruck, Austria;
  2. 2Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California;
  3. 3Department of Clinical Physiology, Nuclear Medicine and PET and Cluster for Molecular Imaging, Department of Biomedical Sciences, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark;
  4. 4Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark;
  5. 5Department of Nuclear Medicine and PET Center, Aarhus University Hospital, Aarhus, Denmark;
  6. 6Department of Endocrinology PE and Department of Surgery C, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark;
  7. 7Ipsen Bioscience, Cambridge, Massachusetts;
  8. 8Bracken Group for Ipsen Bioscience, Newtown, Pennsylvania; and
  9. 9Partner 4 Health for Ipsen Bioscience, Paris, France
  1. For correspondence or reprints, contact Irene Virgolini (irene.virgolini{at}i-med.ac.at).
View Full Text

Statistics from Altmetric.com

Cited By...

  • 7 Citations
  • 7 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • Head-to-Head Comparison of68Ga-NODAGA-JR11 and68Ga-DOTATATE PET/CT in Patients with Metastatic, Well-Differentiated Neuroendocrine Tumors: Interim Analysis of a Prospective Bicenter Study
    Zefang Lin, Wenjia Zhu, Jiaying Zhang, Weibing Miao, Shaobo Yao, Li Huo
    Journal of Nuclear Medicine 2023 64 9
  • Structured Reporting of Computed Tomography in the Staging of Neuroendocrine Neoplasms: A Delphi Consensus Proposal
    Vincenza Granata, Francesca Coppola, Roberta Grassi, Roberta Fusco, Salvatore Tafuto, Francesco Izzo, Alfonso Reginelli, Nicola Maggialetti, Duccio Buccicardi, Barbara Frittoli, Marco Rengo, Chandra Bortolotto, Roberto Prost, Giorgia Viola Lacasella, Marco Montella, Eleonora Ciaghi, Francesco Bellifemine, Federica De Muzio, Ginevra Danti, Giulia Grazzini, Massimo De Filippo, Salvatore Cappabianca, Carmelo Barresi, Franco Iafrate, Luca Pio Stoppino, Andrea Laghi, Roberto Grassi, Luca Brunese, Emanuele Neri, Vittorio Miele, Lorenzo Faggioni
    Frontiers in Endocrinology 2021 12
  • 68Ga-SSO-120 PET for Initial Staging of Small Cell Lung Cancer Patients: A Single-Center Retrospective Study
    David Kersting, Patrick Sandach, Miriam Sraieb, Marcel Wiesweg, Martin Metzenmacher, Kaid Darwiche, Filiz Oezkan, Servet Bölükbas, Martin Stuschke, Lale Umutlu, Michael Nader, Rainer Hamacher, Wolfgang P. Fendler, Johannes Wienker, Wilfried E.E. Eberhardt, Martin Schuler, Ken Herrmann, Hubertus Hautzel
    Journal of Nuclear Medicine 2023 64 10
  • Activity Dose Reduction in 64Cu-DOTATATE PET in Patients with Neuroendocrine Neoplasms: Impact on Image Quality and Lesion Detection Ability
    Mathias Loft, Esben A. Carlsen, Camilla B. Johnbeck, Christoffer V. Jensen, Flemming L. Andersen, Seppo W. Langer, Peter Oturai, Ulrich Knigge, Andreas Kjaer
    Molecular Imaging and Biology 2022 24 4
  • Challenges in developing response evaluation criteria for peptide receptor radionuclide therapy: A consensus report from the European Neuroendocrine Tumor Society Advisory Board Meeting 2022 and the ENETS Theranostics Task Force
    Vikas Prasad, Anna Koumarianou, Timm Denecke, Anders Sundin, Christophe M. Deroose, Marianne Pavel, Emanuel Christ, Angela Lamarca, Martyn Caplin, Justo P. Castaño, Clarisse Dromain, Massimo Falconi, Simona Grozinsky‐Glasberg, Johannes Hofland, Ulrich Peter Knigge, Beata Kos‐Kudla, Balkundi A. Krishna, Nicholas Simon Reed, Aldo Scarpa, Rajaventhan Srirajaskanthan, Christos Toumpanakis, Andreas Kjaer, Rodney J. Hicks, Valentina Ambrosini
    Journal of Neuroendocrinology 2025 37 2
  • Recent Progress in Peptide-Based Molecular Probes for Disease Bioimaging
    Ying Xu, Junfan Chen, Yuan Zhang, Pengcheng Zhang
    Biomacromolecules 2024 25 4
  • A novel read methodology to evaluate the optimal dose of 68Ga-satoreotide trizoxetan as a PET imaging agent in patients with gastroenteropancreatic neuroendocrine tumours: a phase II clinical trial
    Colin G. Miller, Henning Grønbæk, Irene Virgolini, Andreas Kjaer, Pierre Terve, Shadfar Bahri, Peter Iversen, Hanna Svirydenka, Thomas Rohban, Sandy McEwan
    EJNMMI Research 2021 11 1

Article usage

Article usage: July 2021 to April 2025

AbstractFullPdf
Jul 202110610182
Aug 2021264045
Sep 2021149024
Oct 2021174038
Nov 2021120041
Dec 2021166024
Jan 2022109031
Feb 202292019
Mar 202270145180
Apr 202216422274
May 20228220037
Jun 20226830632
Jul 20226135733
Aug 20224220226
Sep 20224331139
Oct 2022227022
Nov 2022348128
Dec 20223838411
Jan 20232638723
Feb 20231835526
Mar 20232437918
Apr 20231325412
May 20231018619
Jun 20231516720
Jul 2023513410
Aug 20231333825
Sep 2023926113
Oct 2023811918
Nov 20238999
Dec 202335514
Jan 20241015411
Feb 2024718611
Mar 2024912745
Apr 2024356942
May 2024129518
Jun 2024325327
Jul 20248110339
Aug 20248912224
Sep 202473514
Oct 2024142819
Nov 202462513
Dec 202452722
Jan 202593825
Feb 2025147614
Mar 2025106125
Apr 2025176534
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 63 (3)
Journal of Nuclear Medicine
Vol. 63, Issue 3
March 1, 2022
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
A Randomized, Factorial Phase II Study to Determine the Optimal Dosing Regimen for 68Ga-Satoreotide Trizoxetan as an Imaging Agent in Patients with Gastroenteropancreatic Neuroendocrine Tumors
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
A Randomized, Factorial Phase II Study to Determine the Optimal Dosing Regimen for 68Ga-Satoreotide Trizoxetan as an Imaging Agent in Patients with Gastroenteropancreatic Neuroendocrine Tumors
Irene Virgolini, Shadfar Bahri, Andreas Kjaer, Henning Grønbæk, Peter Iversen, Esben A. Carlsen, Mathias Loft, Ulrich Knigge, Johanna Maffey-Steffan, Christine Powell, Colin G. Miller, Thomas Rohban, Sandy McEwan, Johannes Czernin
Journal of Nuclear Medicine Mar 2022, 63 (3) 376-383; DOI: 10.2967/jnumed.121.261936

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
A Randomized, Factorial Phase II Study to Determine the Optimal Dosing Regimen for 68Ga-Satoreotide Trizoxetan as an Imaging Agent in Patients with Gastroenteropancreatic Neuroendocrine Tumors
Irene Virgolini, Shadfar Bahri, Andreas Kjaer, Henning Grønbæk, Peter Iversen, Esben A. Carlsen, Mathias Loft, Ulrich Knigge, Johanna Maffey-Steffan, Christine Powell, Colin G. Miller, Thomas Rohban, Sandy McEwan, Johannes Czernin
Journal of Nuclear Medicine Mar 2022, 63 (3) 376-383; DOI: 10.2967/jnumed.121.261936
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Visual Abstract
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • ACKNOWLEDGMENTS
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • 68Ga-SSO-120 PET for Initial Staging of Small Cell Lung Cancer Patients: A Single-Center Retrospective Study
  • Head-to-Head Comparison of 68Ga-NODAGA-JR11 and 68Ga-DOTATATE PET/CT in Patients with Metastatic, Well-Differentiated Neuroendocrine Tumors: Interim Analysis of a Prospective Bicenter Study
  • Google Scholar

More in this TOC Section

  • [18F]FDG PET/CT Predicts Patient Survival in Patients with Systemic Sclerosis–Associated Interstitial Lung Disease
  • Whole-Body [18F]DPA-714 Kinetic Assessment Using PET/CT Scanner with Long Axial Field of View
  • Clinical Outcomes of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Skeletal Metastases from Neuroendocrine Tumors: Insights from Real-World Experience
Show more Clinical Investigation

Similar Articles

Keywords

  • 68Ga-satoreotide trizoxetan
  • neuroendocrine tumors
  • somatostatin receptor antagonist
  • diagnostic imaging
  • optimal dose
SNMMI

© 2025 SNMMI

Powered by HighWire